Aksu, SalihSahin, FahriUz, BurakYavuz, Selim A.Atay, HilmiKelkitli, EnginTurgut, MehmetPehlivan, MustafaAkay, Meltem O.Guray, EmelDemir, MuzafferKahraman, SeldaDemirkan, FatihPaydas, SemraSaydam, GürayHaznedaroglu, Ibrahim C.2019-10-272019-10-2720121306-133X1306-133Xhttps://doi.org/10.4999/uhod.12004https://hdl.handle.net/11454/45522We report our experience in 41 patients with chronic phase (CF)-chronic myeloid leukemia (CML) who had discontinued imatinib switched to dasatinib, retrospectively. The CF-CML patients received dasatinib at starting dose of 100 once daily. Dose adjustment were observed in 11 patients, respectively. In case of other circumstances, treatment has been continued with a lower dose if needed. The median dose of dasatinib was 100 mg daily (range: 50 to 140 mg). We conclude that even low-dose dasatinib therapy is an effective and safe in second line treatment of CML patients patients.en10.4999/uhod.12004info:eu-repo/semantics/openAccessChronic myeloid leukemiaDasatinibTreatment dosageArticle221814WOS:000306389200002Q4